Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| IRB #20130458H | Other Grant/Funding Number | American Diabetes Association |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| American Diabetes Association | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine insulin sensitivity in individuals that are lean normal glucose tolerant subjects after consumption of a normal low fat diet and after a high fat diet and to explore the effects of high fat consumption on the intestinal microbiome, and metabolic endotoxemia.( Aim 1 of the protocol, a separate record is available for Aim 2)
We will test the hypothesis that a high fat diet given to lean, normal glucose tolerant subjects will impair insulin signaling and sensitivity and modify gut microbiome composition and enhance intestinal permeability, which will increase plasma LPS concentration, induce an inflammatory response in peripheral tissues (skeletal muscle). Also we will test the hypothesis that the inflammatory response and insulin resistance caused by high fat ingestion can be ameliorated by administering
All subjects are fed both a low fat diet (considered a normal diet) and high fat diet, first one and then the other in no particular sequence. After a washout period participants are fed the other type of high or low fat diet, depending on which diet they were first assigned to in order to compare the effects of the intervention on insulin sensitivity during each diet.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Placebo: maltodextrin, 6 g three times a day |
|
| Sevelamer | Active Comparator | Sevelamer: (1.6 g sevelamer + 4.4 g maltodextrin three times a day) |
|
| Synbiotic | Active Comparator | Synbiotic: 5g Oligofructose + 4x1010 Bifidobacterium longum CFU 3x daily during diet |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sevelamer | Drug | 1.6 g sevelamer + 4.4 g maltodextrin three times a day |
|
| Measure | Description | Time Frame |
|---|---|---|
| Insulin Sensitivity Low Fat Diet | Skeletal muscle insulin sensitivity measured after 28 days of low fat diet and drug intervention. The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein. | Day 28 |
| Insulin Sensitivity High Fat Diet | Skeletal muscle insulin sensitivity measured after 28 days of high fat diet. The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered. | Day 28 |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma Endotoxin Levels | Endotoxin is a bacterially derived product that we hypothesized would impact insulin sensitivity through pro inflammatory pathways. | At baseline, on day 3, and 28 of the intervention. |
| Gut Permeability |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nicolas Musi, MD. | The University of Texas Health Science Center at San Antonio | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Audie L. Murphy VA Hospital, STVHCS | San Antonio | Texas | 78229 | United States |
Subjects were initially screened by BMI and glucose tolerance via OGTT. Qualified Study participants were then assigned to begin a low or high isocaloric diet and then randomized to one of the 3 arms for 4 weeks. After a 10-12 week washout, subjects are changed over to the other diet and remain in the same arm of the study that they were in previously.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo | placebo, maltodextrin, 6 g three times a day during diet This is a control group. |
| FG001 | Sevelamer | Sevelamer: 1.6 g sevelamer + 4.4 g maltodextrin three times a day during diet |
| FG002 | Synbiotic | 5g Oligofructose + 4x1010 Bifidobacterium longum CFU 3x daily during diet |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Baseline participants were consented and passed screening and completed both high fat and low fat diet while randomized to one of the interventions.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo | placebo, maltodextrin, 6 g three times a day |
| BG001 | Sevelamer | Sevelamer: 1.6 g sevelamer + 4.4 g maltodextrin three times a day |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Insulin Sensitivity Low Fat Diet | Skeletal muscle insulin sensitivity measured after 28 days of low fat diet and drug intervention. The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein. | Posted | Mean | Standard Deviation | M value (mg/kg/min | Day 28 |
|
Adverse Event Data was collected over the course of the study intervention period, beginning with subject's enrollment into study and ending once they completed all visits. This period takes approximately 6 months from screening to completion of all visits.
Adverse events were collected per arm of the study, for placebo, sevelamer and synbiotic, rather than by arm and low or high fat diet. Each arm reports adverse events to include the participant assignment to either low or high fat diets.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo | Maltodextrin: This is a control group that were fed both low and high fat diets. Maltodextrin, 6 g three times a day |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | Non-systematic Assessment |
Despite continued recruitment efforts, we had difficulty with subjects fully completing the study due to dissatisfaction with the diets. Evaluable subjects completed both low and high fat diet while randomized to one of the three interventions, and only insulin sensitivity was captured for both the low fat and high fat diets due to the low completion numbers.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Nicolas Musi | UTHSC San Antonio | 630-5001 | 210 | musi@uthscsa.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Aug 16, 2013 | Sep 29, 2020 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069603 | Sevelamer |
| D058616 | Synbiotics |
| C008315 | maltodextrin |
| D059305 | Diet, High-Fat |
| D018752 | Diet, Fat-Restricted |
| D004032 | Diet |
| ID | Term |
|---|---|
| D011073 | Polyamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D056692 | Prebiotics |
| D019587 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Synbiotic | Drug | 5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day. |
|
| Maltodextrin | Drug | This is a control group. Maltodextrin, 6 g three times a day |
|
| High Fat diet | Other | The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered. |
|
|
| Low Fat diet | Other | The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein. |
|
|
Gut permeability is measured using a lactulose/mannitol ingestion assay where urine samples are collected to analyse the ratio of excreted lactulose:mannitol.
| on Day 24 of the intervention. |
| BG002 | Synbiotic | *synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion CFU/g)three times a day] |
| BG003 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
*synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion CFU/g)three times a day]
|
|
| Primary | Insulin Sensitivity High Fat Diet | Skeletal muscle insulin sensitivity measured after 28 days of high fat diet. The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered. | Posted | Mean | Standard Deviation | M Value (mg/kg/min) | Day 28 |
|
|
|
|
| Secondary | Plasma Endotoxin Levels | Endotoxin is a bacterially derived product that we hypothesized would impact insulin sensitivity through pro inflammatory pathways. | Plasma Endotoxin levels not analyzed after study completed enrollment due to low subject enrollment and limited ability to compare between subjects (max n=3 per group) | Posted | At baseline, on day 3, and 28 of the intervention. |
|
|
| Secondary | Gut Permeability | Gut permeability is measured using a lactulose/mannitol ingestion assay where urine samples are collected to analyse the ratio of excreted lactulose:mannitol. | Gut permeability not analyzed after study completed enrollment due to low subject enrollment and limited ability to compare between subjects (max n=3 per group) | Posted | on Day 24 of the intervention. |
|
|
| 0 |
| 6 |
| 0 |
| 6 |
| 3 |
| 6 |
| EG001 | Sevelamer | Sevelamer: 1.6 g sevelamer + 4.4 g maltodextrin three times a day that were fed either a low fat or high fat diet, followed by the other type of diet. | 0 | 7 | 0 | 7 | 3 | 7 |
| EG002 | Synbiotic | Synbiotic: 5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day that were fed either a low fat or high fat diet, followed by the other type of diet. | 0 | 7 | 0 | 7 | 4 | 7 |
| Diarrhea | Gastrointestinal disorders | Non-systematic Assessment |
|
| Headache | Nervous system disorders | Non-systematic Assessment |
|
| Hematoma | Surgical and medical procedures | Non-systematic Assessment | Hematoma at muscle biopsy site |
|
| Mouth Ulcers | Gastrointestinal disorders | Non-systematic Assessment |
|
| Ear Itching | Ear and labyrinth disorders | Non-systematic Assessment |
|
| Abdominal Bloating/Flatulence | Gastrointestinal disorders | Non-systematic Assessment |
|
| Hypertension | Vascular disorders | Non-systematic Assessment |
|
| Vasovagal Syncope | Surgical and medical procedures | Non-systematic Assessment | Syncope during medical procedure |
|
| Dehydration | General disorders | Non-systematic Assessment |
|
| Gum Infection | Gastrointestinal disorders | Non-systematic Assessment | Treated with Abx and removed off protocol |
|
Not provided
Not provided
Not provided
| Dietary Supplements |
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
| D019936 | Probiotics |
| D019602 | Food and Beverages |
| D009747 | Nutritional Physiological Phenomena |
| D004035 | Diet Therapy |
| D044623 | Nutrition Therapy |
| D013812 | Therapeutics |